HYPAQUE ORAL POWDER 997.4 MG
DIATRIZOATE SODIUM : 997.4 MG · DIN 02180685 · GE HEALTHCARE CANADA INC
Health Canada status: CANCELLED POST MARKET
What is HYPAQUE ORAL POWDER?
HYPAQUE ORAL POWDER 997.4 MG contains DIATRIZOATE SODIUM : 997.4 MG. It is listed in the Health Canada Drug Product Database under DIN 02180685, held by GE HEALTHCARE CANADA INC, supplied as POWDER for RECTAL ; ORAL administration. Health Canada currently lists it as cancelled post market, status dated 27-Jul-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is HYPAQUE ORAL POWDER used for?
Radiography of gastrointestinal tract following oral or rectal administration.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02180685 |
|---|---|
| Brand name | HYPAQUE ORAL POWDER |
| Generic / active ingredient | DIATRIZOATE SODIUM : 997.4 MG |
| Manufacturer | GE HEALTHCARE CANADA INC |
| Strength | 997.4 MG |
| Dosage form | POWDER |
| Route of administration | RECTAL ; ORAL |
| Schedule | Ethical |
| ATC code | V08AA01 DIATRIZOIC ACID |
| AHFS class | 36:68.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 27-Jul-2011 |
| Original market date | 1998-02-19 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02180685 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2180685 |
| Brand name | HYPAQUE ORAL POWDER |
| Active ingredient / INN | DIATRIZOATE SODIUM : 997.4 MG |
| ATC code | V08AA01 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V08 |
| AHFS class | 36:68.00 |
| Health Canada schedule | Ethical |
| Biosimilar biologic | No |
| Market authorization holder | GE HEALTHCARE CANADA INC |
How is it stored and handled?
null
How is it supplied?
Containers of 250 g.
Which pack is which?
| Strength on the label | 997.4 MG |
|---|---|
| Dosage form | POWDER |
| Route | RECTAL ; ORAL |
| Packaging as described in the monograph | Containers of 250 g. |
| Storage | null |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code V08AA01 DIATRIZOIC ACID. 1 of 30 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| GASTROGRAFIN | 10 % | SOLUTION | BRACCO IMAGING CANADA | MARKETED | DIN 02228564 |
| GASTROGRAFIN LIQ | 10 % | LIQUID | SQUIBB DIAGNOSTICS, DIVISION OF BRISTOL-MYERS SQUIBB CANADA INC. | CANCELLED POST MARKET | DIN 01995669 |
| HYPAQUE ORAL LIQUID - 50G/120ML | 50 G / 120 ML | LIQUID | NYCOMED IMAGING A.S. | CANCELLED POST MARKET | DIN 02180626 |
| HYPAQUE ORAL LIQUID 50GM/120ML | 50 G / 120 ML | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02026902 |
| HYPAQUE ORAL POWDER 0.9974G/G | 997.4 MG | POWDER | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02026988 |
| HYPAQUE PWR 100% | 100 % | POWDER | STERLING WINTHROP INC. | CANCELLED POST MARKET | DIN 01905007 |
| HYPAQUE SODIUM 50% - LIQ IV | 50 % | LIQUID | NYCOMED IMAGING A.S. | CANCELLED POST MARKET | DIN 02180650 |
| HYPAQUE SODIUM 50% LIQ | 50 % | LIQUID | STERLING WINTHROP INC. | CANCELLED POST MARKET | DIN 01902768 |
| HYPAQUE SODIUM LIQ 50% | 50 % | LIQUID | SANOFI CANADA, INC. | CANCELLED POST MARKET | DIN 02017784 |
| HYPAQUE-M 18% | 18 % | SOLUTION | AMERSHAM HEALTH INC | CANCELLED POST MARKET | DIN 02180634 |
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.